SWOG clinical trial number
SWOG-9342

A Study of the Late Cardiac Effects of Two Different Adjuvant Chemotherapy Regimens in Women With Node Negative Breast Cancer Treated on SWOG-8897

Closed
Phase
Accrual
43%
Published
Abbreviated Title
Cardiac Evaluation with MUGA scan at year 5-8 and year 10-11 OR at years 10-14 only
Activated
02/15/1997
Closed
11/15/2003
Participants
NCORP, Members, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists

Research committees

Breast Cancer

Eligibility Criteria Expand/Collapse

Patients on SWOG-8897; patients must be free of disease and without a past recurrence; patients may be registered up to 8 years post randomization on SWOG-8897 OR between 10-14 years post-randomizaton on SWOG-8897.

CANCER CONTROL CREDIT: 0.5
TREATMENT CREDIT: 0.0

Publication Information Expand/Collapse

2008

Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group (SWOG) protocol S8897 [PMID 18227530]

PA Ganz;MA Hussey;CM Moinpour;JM Unger;LF Hutchins;SR Dakhil;JK Giguere;JW Goodwin;S Martino;KS Albain Journal of Clinical Oncology 26:1223-1230

2002

Late cardiac effects of adjuvant CMF vs CAF in women with node negative breast cancer treated on SWOG 8897: initial results from SWOG 9342

PA Ganz;SJ Green;L Hutchins;S Martino;J Gralow;R Livingston;KS Albain Breast Cancer Research and Treatment 76(1):S157(#639)

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase